Valuation: StemCell Institute Inc.

Market Cap 7.54B 46.45M 40.6M 37.46M 34.53M 65.08M 4.47B 66.53M 448M 176M 2.19B 174M 171M P/E 2026
49.6x
P/E 2027 * 68.7x
Enterprise Value 7.54B 46.45M 40.6M 37.46M 34.53M 65.08M 4.47B 66.53M 448M 176M 2.19B 174M 171M EV / Sales 2026
2.79x
EV / Sales 2027 * 2.43x
Free-Float
23.41%
Yield 2026 *
-
Yield 2027 * -
1 day-0.40%
1 week-2.47%
Current month+3.45%
1 month+8.39%
3 months-4.46%
6 months-13.81%
Current year-5.55%
1 week 733
Extreme 733
773
1 month 680
Extreme 680
775
Current year 627
Extreme 627
976
1 year 627
Extreme 627
1,085
3 years 627
Extreme 627
3,220
5 years 627
Extreme 627
3,365
10 years 627
Extreme 627
3,610
Manager TitleAgeSince
Director of Finance/CFO - -
President 53 31/05/2016
Director TitleAgeSince
Director/Board Member 53 31/08/2013
Director/Board Member 81 31/05/2015
Director/Board Member 66 31/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%-2.47%-26.86%-76.59% 46.45M
+0.91%+3.19%+73.45%+44.49% 137B
-3.77%-8.71%+2.79%+29.46% 82.34B
+2.31%+2.37%+4.71%+51.78% 26.9B
+0.61%+1.56%+26.22%+47.23% 23.32B
+0.79%+0.28%-15.04%-28.97% 19.94B
-2.15%-4.57%+11.34%+142.52% 16.79B
-0.25%-0.67%+8.79%+8.59% 15.38B
+1.26%+1.79%+67.87%+126.20% 15.21B
+0.27%-1.47%-6.46%-14.23% 12.84B
Average -0.04%-1.15%+14.68%+33.05% 34.99B
Weighted average by Cap. -0.31%-1.01%+34.33%+42.02%

Financials

2026 2027 *
Net sales 2.87B 17.68M 15.45M 14.25M 13.14M 24.76M 1.7B 25.31M 170M 67.01M 834M 66.38M 64.93M 3.1B 19.09M 16.69M 15.4M 14.19M 26.75M 1.84B 27.34M 184M 72.38M 901M 71.7M 70.13M
Net income 180M 1.11M 969K 894K 824K 1.55M 107M 1.59M 10.69M 4.2M 52.29M 4.16M 4.07M 110M 677K 592K 546K 504K 949K 65.24M 970K 6.53M 2.57M 31.95M 2.54M 2.49M
Net Debt - -
Logo StemCell Institute Inc.
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Employees
117
Date Price Change Volume
17/07/26 JP¥749.00 -0.40% 6,400
16/07/26 JP¥752.00 -2.08% 2,500
15/07/26 JP¥768.00 +0.39% 1,900
14/07/26 JP¥765.00 -0.65% 4,300
13/07/26 JP¥770.00 +0.26% 2,400

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7096 Stock